Huang Hongxiang, Zhong Peiyuan, Zhu Xie, Fu Silv, Li Siling, Peng Sujuan, Liu Yangyang, Lu Zhihui, Chen Li
Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Department of Radiation Oncology, Jiangxi Provincial Cancer Hospital, Nanchang, China.
Front Oncol. 2023 Mar 23;13:1137224. doi: 10.3389/fonc.2023.1137224. eCollection 2023.
Despite the fact that numerous clinical and preclinical studies have demonstrated the synergistic effects of combining antiangiogenic or chemotherapy with immunotherapy, no data have been found to indicate that combination therapy is more effective and safer as second-line therapy.
We retrospectively compared the effectiveness and safety of ICIs plus rh-endostatin to ICIs plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). The evaluation indicators of this study were progression-free survival (PFS), safety profile, objective response rate (ORR), disease control rate (DCR), and 1-year overall survival (OS).
The median PFS with immunotherapy plus rh-endostatin (IE) was 7.10 months (95% CI, 4.64 to 9.56) versus 5.13 months (95% CI, 4.29 to 5.97) with immunotherapy plus chemotherapy (IC) (HR, 0.56; 95%CI, 0.33 to 0.95). Treatment-related adverse events of grade 3 or 4 occurred in 7.5% of the IE group versus 25.0% of the IC group. The ORR in the IE group was 35.0% versus 20.8% in the IC group (P = 0.137), and the DCR in the IE group was 92.5% versus 77.1% in the IC group (P = 0.049). The 1-year OS rate for the IE group was 69.4%, which was higher than the 61.4% of the IC group.
Our study showed that ICI therapy combined with endostatin therapy exhibits high efficacy and safety, suggesting that such a combination might be a viable treatment option for patients with pre-treated NSCLC in the future.
尽管大量临床和临床前研究已证明抗血管生成或化疗与免疫疗法联合具有协同作用，但尚无数据表明联合疗法作为二线治疗更有效且更安全。
我们回顾性比较了免疫检查点抑制剂（ICIs）联合重组人血管内皮抑素（rh-endostatin）与ICIs联合化疗在晚期非小细胞肺癌（NSCLC）患者中的有效性和安全性。本研究的评估指标为无进展生存期（PFS）、安全性、客观缓解率（ORR）、疾病控制率（DCR）和1年总生存期（OS）。
免疫疗法联合rh-endostatin（IE）组的中位PFS为7.10个月（95%CI，4.64至9.56），而免疫疗法联合化疗（IC）组为5.13个月（95%CI，4.29至5.97）（HR，0.56；95%CI，0.33至0.95）。3级或4级治疗相关不良事件在IE组中发生率为7.5%，而IC组为25.0%。IE组的ORR为35.0%，IC组为20.8%（P = 0.137），IE组的DCR为92.5%，IC组为77.1%（P = 0.049）。IE组的1年OS率为69.4%，高于IC组的61.4%。
我们的研究表明，ICI疗法联合内皮抑素疗法具有高疗效和安全性，提示这种联合可能是未来预处理NSCLC患者的一种可行治疗选择。
